| Manufacturer || Ipsen Pharma
| Disease || Kidney Cancer
| Indication || Renal cell carcinoma
| Mode of Action || Tyrosine kinase inhibitor
| Approval Status || EMA approved (EU); FDA approved (USA)
| CAS Number || 849217-68-1
| Strength || 20 mg, 40 mg, 60 mg
Who is cabozantinib for?
Cabometyx (cabozantinib) is indicated for the treatment of patients with advanced renal cell carcinoma (a type of kidney cancer) who have received prior anti-angiogenic therapy 
(therapy that inhibits the formation of new blood vessels that supply the tumour with oxygen and nutrients 
Complete information about Cabometyx (cabozantinib) dosage and administration can be found here 
The standard dosage is:
Consult your treating doctor for personalised dosing.
- 60 mg orally, once daily
- Patients should not eat for at least 2 hours before and at least 1 hour after assumption
- Cabozantinib tablets should not be substituted with cabozantinib capsules.
What is cabozantinib and how does it work?
Cabometyx (cabozantinib) is a cancer medicine used to treat adults with advanced renal cell carcinoma (a type of kidney cancer) who have received prior anti-angiogenic therapy 
. The active substance in Cabometyx, cabozantinib, is a ‘tyrosine kinase inhibitor’. This means that it blocks the activity of enzymes known as tyrosine kinases. These enzymes can be found in cancer cells, where they activate several processes including cell division and the growth of new blood vessels to supply the cancer. By blocking the activity of these enzymes in cancer cells, Cabometyx (cabozantinib) reduces the growth and spread of the cancer 
What is cabozantinib's approval status?
Cabometyx (cabozantinib) was approved by:
- FDA (USA) on April 25, 2016 
- EMA (EU) on September 9, 2016 
for advanced renal cell carcinoma previously treated with an anti-angiogenic therapy.The approvals were based on a study involving 658 adults with advanced renal cell carcinoma that had got worse despite treatment with an anti-angiogenic therapy. In the study, Cabometyx (cabozantinib) was compared with the cancer medicine everolimus
. Results showed a progression-free survival (time patients lived without their disease getting worse) of 7.4 months on average (95 % CI: 6.6, 9.1) compared with 3.8 months (95 % CI: 3.7, 5.1) in patients treated with everolimus 
. The overall response rate (ORR) was 24 % (95 % CI: 19, 29) with cabozantinib and 4 % (95 % CI: 2, 7) 
. Preliminary results indicated that patients treated with Cabometyx (cabozantinib) lived overall longer than patients treated with everolimus (an average of 21.4 months compared with 16.5 months) 
Summary of Product Characteristics [EMA]: Cabometyx (cabozantinib), Ipsen Pharma, Oct. 2016. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004163/WC500214071.pdf
Summary of Product Characteristics [FDA]: Cabometyx (cabozantinib), Exelixis Inc., Apr. 2016. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208692s000lbl.pdf
EMA. Human Medicines: Cabometyx (cabozantinib), 12/10/2016 (last update: 12/10/2016), cited on 19/01/2017. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004163/human_med_002018.jsp&mid=WC0b01ac058001d124
Drugs.com. Cabometyx (cabozantinib), 05/07/2016, (last update: 01/06/2017), cited on 19/01/2017. https://www.drugs.com/mtm/cabometyx.html
Cancer.gov. Angiogenesis inhibitors. (last update 7/10/2011), cited on 24/10/2017. https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/angiogenesis-inhibitors-fact-sheet